Interferon Regulatory Factors as a Potential Therapeutic Target for Neuroinflammation: A Focus on Alzheimer's Disease
- PMID: 40243463
- PMCID: PMC11988619
- DOI: 10.3390/ijms26072906
Interferon Regulatory Factors as a Potential Therapeutic Target for Neuroinflammation: A Focus on Alzheimer's Disease
Abstract
Interferon Regulatory Factors (IRFs) are critical modulators of immune and inflammatory responses, yet their roles in Alzheimer's disease (AD) and other neurodegenerative disorders remain incompletely understood. While IRFs are recognized for their regulatory functions in neuroinflammation, microglial activation, and neuronal survival, their dual roles as both drivers of pathological inflammation and mediators of neuroprotective pathways underscore a sophisticated regulatory paradox in neurodegenerative disorders. This review aims to synthesize current evidence on IRF-mediated neuroinflammation in AD and related diseases, focusing on the multifaceted functions of key IRF family members, including IRF1, IRF3, and IRF7. We critically evaluate their divergent roles: IRF1 and IRF3, for instance, exacerbate neuroinflammatory cascades and amyloid-beta (Aβ) pathology in AD, whereas IRF7 may paradoxically suppress inflammation under specific conditions. Additionally, we explore IRF dysregulation in Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease, emphasizing shared and distinct mechanisms across neurodegenerative disorders. Restoring IRF balance through genetic manipulation, small-molecule inhibitors, or microbiome-derived modulators could attenuate neuroinflammation, enhance Aβ clearance, and protect neuronal integrity. Ultimately, this work provides a framework for future research to harness IRF signaling pathways in the development of precision therapies for AD and other neurodegenerative diseases.
Keywords: Alzheimer’s disease; interferon regulatory factors; neuroinflammation; therapeutic targets.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Therapeutic potential of plant-derived natural compounds in Alzheimer's disease: Targeting microglia-mediated neuroinflammation.Biomed Pharmacother. 2024 Sep;178:117235. doi: 10.1016/j.biopha.2024.117235. Epub 2024 Aug 1. Biomed Pharmacother. 2024. PMID: 39094545 Review.
-
IRF-8 is Involved in Amyloid-β1-40 (Aβ1-40)-induced Microglial Activation: a New Implication in Alzheimer's Disease.J Mol Neurosci. 2017 Oct;63(2):159-164. doi: 10.1007/s12031-017-0966-1. Epub 2017 Aug 31. J Mol Neurosci. 2017. PMID: 28856571
-
Platycodon grandiflorum root extract inhibits Aβ deposition by breaking the vicious circle linking oxidative stress and neuroinflammation in Alzheimer's disease.Biomed Pharmacother. 2024 Aug;177:117090. doi: 10.1016/j.biopha.2024.117090. Epub 2024 Jul 4. Biomed Pharmacother. 2024. PMID: 38968796
-
Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view.J Neural Transm (Vienna). 2024 Dec;131(12):1429-1453. doi: 10.1007/s00702-023-02723-5. Epub 2024 Jan 23. J Neural Transm (Vienna). 2024. PMID: 38261034 Free PMC article. Review.
-
IRF3 regulates neuroinflammatory responses and the expression of genes associated with Alzheimer's disease.J Neuroinflammation. 2024 Aug 30;21(1):212. doi: 10.1186/s12974-024-03203-7. J Neuroinflammation. 2024. PMID: 39215356 Free PMC article.
References
-
- Nandi A., Counts N., Chen S., Seligman B., Tortorice D., Vigo D., Bloom D.E. Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: A value of statistical life approach. eClinicalMedicine. 2022;51:101580. doi: 10.1016/j.eclinm.2022.101580. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical